Koios Beverage CEO: The Nootropic Market is Expected to Grow by 600 Percent within 10 Years

Koios Beverage CEO Chris Miller provides an outline of the company’s strategy and its proprietary products. Koios Beverage (CSE: KBEV ,OTCMKTS:SNOVF) CEO Chris Miller believes that there is vast opportunity in the nootropics market. In the interview below, he defines nootropics, outlines their value and discusses how Koios uses them as part of its supplements and beverage formulas as a healthy alternative to caffeine. Miller also addresses Koios’ clinical trial, which is being conducted to study the efficacy of the company’s products, the recent addition of a powder-based supplement to its product line and the rebranding of its beverages. Below is a transcript of our interview with Koios Beverage CEO Chris Miller. It has been edited for clarity and brevity. Investing News Network: Please give our investor audience an overview of Koios and its proprietary nootropic products. Koios Beverage CEO Chris Miller: I started Koios five years ago with the mission of using our proprietary products to help people get healthier. It all began when I started looking for a natural alternative to Adderall for enhancing brain function and thus treating my ADHD. Once I found a formula that I liked, I took it to the top labs, doctors and biochemists in the country and worked with them to develop a nootropics-based supplement that was widely distributed by Max Muscle and Europa Sports. We’d essentially pioneered a new technology that didn’t overstimulate the brain and contained low levels of caffeine. Soon after we launched distribution, we realized there was a huge demand in the market for nootropics. If you ask people whether they would take a supplement to enhance their brain function at work, increase their productivity and thus make more money, there is a high likelihood that they will say yes. To help meet this demand, we followed […]

Click here to view full article